The RFK February 2026 peptide announcement: what it means

A public signal is not the same as a final rule. Here is the gap between the two.

TL;DR

• In February 2026, HHS Secretary Robert F. Kennedy Jr. said in a podcast interview that FDA would soon make more peptides accessible. That was not a formal proposal; the formal step was FDA's April 2026 change to its category list.
• FDA removed 12 peptides from Category 2 on April 22, 2026, after their nominations were withdrawn.
• FDA's advisory committee met on July 23–24, 2026, and voted to recommend six of the seven peptides it reviewed. As of September 14, 2026, FDA has not made a final decision.

What it is

On February 27, 2026, the Health and Human Services Secretary, Robert F. Kennedy Jr., said in a podcast interview that FDA would soon make about 14 peptides more accessible. In plain English, he runs the federal agency that oversees the FDA. He said FDA had wrongly moved 19 peptides onto its Category 2 list in September 2023. Category 2 is FDA's list of bulk drug substances that it says raise significant safety risks. Think of Category 2 as a hold shelf. His remark was not a formal proposal, and available reports do not show that he named specific peptides.

How it works

Moving a peptide off the list is a process, not a press release. The nominators of 12 of these peptides withdrew their nominations. On April 15, 2026, FDA gave notice that those 12 would leave Category 2, and it removed them on April 22, 2026 (FDA 503A bulk substances list). FDA updated its category list again on May 14, 2026. In an April 16, 2026 Federal Register notice, FDA scheduled a review by its Pharmacy Compounding Advisory Committee. In plain English, that is an outside panel that advises the FDA on what may be compounded. The panel met on July 23–24, 2026, and reviewed seven peptides.

Who asks about it

People follow this story because the headlines and the reality drifted apart. A patient hears "peptides are legal again." Then a pharmacy says it still cannot compound them. The honest question is: which is true? Both, in part. The public talk changed in February, and FDA's category list changed in April. But the formal paperwork that pharmacies rely on moves on its own clock.

What the research says

This is a regulatory story, not a clinical trial. So the "evidence" here is the public record. Industry press reported the FDA moving to ease limits on these peptides after the requests were withdrawn (BioPharma Dive, 2026). The 12 peptides FDA removed on April 22, 2026, include BPC-157 and TB-500. Thymosin alpha-1, CJC-1295, and ipamorelin were removed earlier, on September 27, 2024. Final access depends on the FDA's formal notices, not on any single announcement.

What to know before considering it

Status changes the moment the FDA's record changes. That can be slower than the news cycle. Until a peptide is formally cleared, a licensed pharmacy may not be able to compound it. Access stays limited until then. None of this says whether any peptide is right for you. That is a question for a licensed physician who knows your history.

The Halftime POV

We track these announcements closely. Our members deserve the accurate version, not the hyped one. The February signal was real and it mattered. So does the fact that the formal process is still underway. We would rather tell you where the line sits today than let a headline set your hopes.

Related reading:

• The RFK peptide reclassification timeline
• Secretary Kennedy's February 2026 remarks, explained
• Category 1 vs Category 2 peptides

---

FAQ

Q: What did RFK Jr. say about peptides in February 2026? A: On February 27, 2026, HHS Secretary Robert F. Kennedy Jr. said on The Joe Rogan Experience podcast that FDA would act on peptides soon and that about 14 peptides would become more accessible. He also said FDA had wrongly moved 19 peptides into Category 2 in September 2023. It was an interview remark, not a formal HHS proposal. HHS did not publish a list or a Federal Register notice. The formal step came from FDA: on April 22, 2026, FDA removed 12 peptides from Category 2 after their nominations were withdrawn.

Q: Are these peptides available to compound now? A: Not automatically. FDA removed 12 peptides from Category 2 on April 22, 2026, and updated its category list again on May 14, 2026. As of September 14, 2026, none of the 12 is on the 503A bulks list. FDA's Pharmacy Compounding Advisory Committee met on July 23–24, 2026, and reviewed seven peptides. It voted to recommend six of them and voted against emideltide (DSIP). As of September 2026, FDA has not made a final decision on BPC-157 or TB-500. At its July 23–24, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee voted separately on each. Both votes were 8 yes, 6 no, and 1 abstention to recommend adding the peptide to the Section 503A bulk drug substances list. The committee is advisory, and formal addition to the list requires further FDA action.

Q: Which peptides are affected? A: Available reports do not show that Secretary Kennedy named specific peptides. FDA's formal record shows two sets of removals from Category 2. On September 27, 2024, FDA removed AOD-9604, CJC-1295, ipamorelin acetate, thymosin alpha-1, and Selank. On April 22, 2026, FDA removed BPC-157, cathelicidin LL-37, dihexa acetate, emideltide (DSIP), Epitalon, GHK-Cu (injectable routes), KPV, PEG-MGF, melanotan II, MOTS-c, Semax, and TB-500. As of September 14, 2026, ibutamoren (MK-677) and kisspeptin-10 remain in Category 2.

---

Disclaimer

Several peptides discussed in this article — including thymosin alpha-1, CJC-1295, and ipamorelin — were previously in FDA's Category 2. FDA removed them from Category 2 on September 27, 2024. As of September 14, 2026, they are not in any FDA 503A category and are not on the 503A bulks list. None of them was on the agenda of FDA's July 23–24, 2026 Pharmacy Compounding Advisory Committee meeting. As of September 2026, FDA has not made a final decision on BPC-157 or TB-500. At its July 23–24, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee voted separately on each. Both votes were 8 yes, 6 no, and 1 abstention to recommend adding the peptide to the Section 503A bulk drug substances list. The committee is advisory, and formal addition to the list requires further FDA action. This article is educational and is not medical advice. Halftime Health only prescribes through licensed physicians in states where our partner physicians are credentialed.

Get started

We share what we learn along the way — the research, the regulations, the real-world trade-offs. Get started with Halftime Health.

---

Sources

• FDA. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A
• FDA moves toward easing restrictions on certain peptides — BioPharma Dive, 2026

---

This article discusses compounds whose FDA compounding status has been under review (see our FDA categorization explainer). Halftime Health protocols are prescribed by licensed physicians and prepared by licensed 503A compounding pharmacies. Compounded drugs are not FDA-approved and have not been evaluated by FDA for safety or effectiveness. This article is provided for educational purposes only and does not constitute medical advice or an offer to sell.